For research use only. Not for use in humans.

Cabiralizumab (Anti-CSF1R / M-CSFR / CD115)

Synonyms: FPA 008

Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) is an monoclonal antibody (MAb) targeting CSF1R. It can be used in the research of rheumatoid arthritis (RA), melanoma, kidney cancer, or non-small cell lung cancer. MW :146.3 KD.

Cabiralizumab (Anti-CSF1R / M-CSFR / CD115)

Quality Control

Batch: A264401 Purity: 99% Protein concentration: 5.74mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CSF-1R Others
Linifanib (ABT-869) 33 VEGFR1/FLT1,FLT3,VEGFR2/KDR
ENMD-2076 9 FLT3,RET,Aurora A
OSI-930 7 FLT1,KDR,LCK
GW2580 17
Agerafenib (CEP-32496) 6 RET,PDGFRβ,LCK
Vimseltinib 0 c-Kit
Edicotinib(JNJ-40346527) 2
Chiauranib 0 c-Kit,VEGFR2,Aurora B
ARRY-382 0
Elzovantinib (TPX-0022) 0 SRC,MET
Ki20227 1 VEGFR2,PDGFRβ,c-Kit
Sulfatinib 1 VEGFR3,VEGFR1,FGFR1
PLX5622 14 FLT3,KIT,AURKC
PRN1371 2 FGFR1,FGFR2,FGFR3
Sotuletinib (BLZ945) 34
Pimicotinib 0
CSF1R-IN-1 1
AZD7507 0
PDGFR inhibitor 1 3 PDGFR,Kit,VEGFR2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) is an monoclonal antibody (MAb) targeting CSF1R. It can be used in the research of rheumatoid arthritis (RA), melanoma, kidney cancer, or non-small cell lung cancer. MW :146.3 KD.
References

Product Details

CAS No. 1613144-80-1
Molecular Weight 146.3
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.